HT-55 Xenograft Model Service for Colon Cancer

The HT-55 xenograft model offers a robust preclinical platform for evaluating therapeutic efficacy against colorectal adenocarcinoma, faithfully recapitulating the genetic and phenotypic complexity of human rectal tumors. Alfa Cytology leverages this well-characterized cell line to deliver validated, reproducible xenograft studies that accelerate your colon cancer drug development pipeline from target validation through lead optimization.

Overview of HT-55 Xenograft Model for Colon Cancer

The HT-55 cell line, originally established from a rectal adenocarcinoma specimen, represents a well-differentiated epithelial model of colorectal cancer that retains key molecular hallmarks of the disease. This cell line harbors characteristic mutations in the APC, TP53, BRAF, and DNMT3A genes, reflecting the multistep carcinogenesis typical of sporadic colorectal tumors. HT-55 cells exhibit chromosomal instability with a near-triploid karyotype and demonstrate tumorigenic potential in immunocompromised mouse strains, forming subcutaneous xenografts that closely mirror the growth kinetics and histopathological features of patient-derived rectal adenocarcinomas.

As a xenograft model, HT-55 enables researchers to investigate tumor-microenvironment interactions, evaluate angiogenic responses, and assess drug penetration and efficacy in a physiologically relevant three-dimensional context. The model has been extensively utilized in pharmacological studies investigating anti-VEGF therapies, cytotoxic agents, and targeted small molecules, demonstrating predictable dose-response relationships and serving as a reliable surrogate for clinical translation in colorectal oncology research.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting colorectal adenocarcinoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving colon cancer progression through APC, TP53, BRAF, and DNMT3A mutations, and how treatments intersect with chromosomal instability.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment.

Figure 1. Subtype differences in TEV composition. (Asif, Paris J., et al., 2025)

Cell Line Information: HT-55

The HT-55 cell line is a well-established human colorectal adenocarcinoma line with comprehensive molecular characterization. Its near-triploid karyotype, characteristic mutations in APC, TP53, BRAF, and DNMT3A, and tumorigenic potential in immunocompromised mice make it unique among available colon cancer cell lines and essential for preclinical research targeting rectal adenocarcinoma.

Our Services

Alfa Cytology provides end-to-end HT-55 xenograft model services encompassing cell line authentication, in vivo tumor establishment, treatment administration, and comprehensive endpoint analysis. Our experienced scientific team ensures rigorous quality control at every stage, delivering high-quality data packages that meet regulatory and publication standards for your preclinical colon cancer research programs.

Workflow of HT-55 Xenograft Model Construction

The construction of the HT-55 xenograft model follows a standardized, quality-controlled workflow designed to ensure reproducible tumor growth and reliable pharmacological readouts. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Line Authentication and Expansion: HT-55 cells are revived from authenticated master cell banks and expanded under adherent culture conditions. Short tandem repeat (STR) profiling is performed to confirm cell identity, and mycoplasma testing ensures culture purity before inoculation.
2. Recipient Mouse Preparation: Immunocompromised NCr Nude mice (female, 6--8 weeks old) are acclimatized under specific-pathogen-free (SPF) conditions for at least one week. Body weight and general health status are recorded to establish baseline parameters.
3. Tumor Cell Inoculation: HT-55 cells are harvested at logarithmic growth phase, washed, and resuspended in a 1:1 mixture of serum-free medium and Matrigel at a concentration of 5x10^6 cells per 100 uL. The cell suspension is injected subcutaneously into the right flank of each mouse using a sterile 25-gauge needle.
4. Tumor Establishment Monitoring: Mice are monitored daily for general health, and tumor dimensions are measured twice weekly using digital calipers. Tumor volume is calculated using the modified ellipsoid formula (V = 0.5 x L x W^2). Mice are randomized into treatment groups once tumors reach 100--150 mm^3.
5. Treatment Administration: Test compounds are administered via the designated route (oral gavage, intraperitoneal, or intravenous injection) according to the study protocol. Dosing schedules are optimized based on compound pharmacokinetics and prior tolerability data.
6. Endpoint Assessment and Sample Collection: At study termination, tumors are excised, weighed, and processed for histopathological analysis (H&E staining, IHC for Ki-67, CD31, TUNEL). Blood samples are collected for pharmacokinetic and biomarker analysis. Tumor growth inhibition (TGI) and tumor regression rates are calculated relative to vehicle controls.

Figure 2: Schematic workflow illustrating the derivation and construction of the HT-55 Xenograft Model at Alfa Cytology.

Case Study-HT-55 Xenograft Model Development

Alfa Cytology has successfully established and validated the HT-55 subcutaneous xenograft model under multiple study configurations, demonstrating consistent tumor take rates and dose-dependent responses to reference compounds. Our historical dataset encompasses growth kinetic profiling, reference compound benchmarking, and biomarker correlation analyses, providing clients with a robust foundation for comparative efficacy studies. Detailed study parameters, statistical outcomes, and representative histopathological data are available upon request under confidentiality agreements.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your HT-55 xenograft studies ensures access to a scientifically rigorous, operationally efficient, and client-focused preclinical service platform.

• Verified Cell Line Integrity: Validated cell line authentication with STR profiling and mycoplasma screening for every study batch.
• High Take Rates and Consistency: Standardized xenograft protocols optimized for HT-55 tumor growth kinetics and pharmacological responsiveness.
• Comprehensive Analytical Support: Comprehensive endpoint analysis including tumor histopathology, biomarker immunostaining, and PK/PD correlation.
• Tailored Study Designs: Flexible study designs accommodating single-agent, combination, and dose-escalation paradigms.
• Standardized Protocols: Dedicated project management with regular progress updates and transparent data reporting.
• Dedicated Project Management: Competitive timelines from study initiation to final report delivery, accelerating your decision-making process.

Contact Us

Ready to advance your colon cancer therapeutic program with a validated HT-55 xenograft model? Contact us today to discuss your study requirements, receive a customized proposal, and learn how Alfa Cytology can accelerate your preclinical research. Please reach out to us today via our inquiry form or email to learn more about our HT-55 Xenograft Model services.

For research use only. Not intended for any clinical use.